These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21847900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD, Levy MC, Schwab GG, Paik Y.
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract] [Full Text] [Related]

  • 7. The commercial speech doctrine in health regulation: the clash between the public interest in a robust First Amendment and the public interest in effective protection from harm.
    Orentlicher D.
    Am J Law Med; 2011; 37(2-3):299-314. PubMed ID: 21847883
    [No Abstract] [Full Text] [Related]

  • 8. An unhealthy disregard.
    Nat Med; 2010 Jun; 16(6):609. PubMed ID: 20526289
    [No Abstract] [Full Text] [Related]

  • 9. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA.
    Issue Brief Health Policy Track Serv; 2010 Jan 04; ():1-31. PubMed ID: 20217914
    [No Abstract] [Full Text] [Related]

  • 10. Off-Label Marketing's Audiences: The 21st Century Cures Act and the Relaxation of Standards for Evidence-Based Therapeutic and Cost-Comparative Claims.
    Halabi SF.
    Am J Law Med; 2018 May 04; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan 04; 20(112):25. PubMed ID: 21462792
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Health related claims, the market for information, and the first amendment.
    Beales JH.
    Health Matrix Clevel; 2011 Jan 04; 21(1):7-30. PubMed ID: 21847896
    [No Abstract] [Full Text] [Related]

  • 18. GlaxoSmithKline is fined record $3bn in US.
    Roehr B.
    BMJ; 2012 Jul 03; 345():e4568. PubMed ID: 22761252
    [No Abstract] [Full Text] [Related]

  • 19. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK, Liang BA.
    Mayo Clin Proc; 2016 Jun 03; 91(6):701-6. PubMed ID: 27084416
    [No Abstract] [Full Text] [Related]

  • 20. To ban or not to ban--that is the question: the constitutionality of a moratorium on consumer drug advertising.
    Schwartz MI.
    Food Drug Law J; 2008 Jun 03; 63(1):1-33. PubMed ID: 18561453
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.